

Haematologica  
HAEMATOL/2019/243428  
Version 3

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies

Roberto Mina, Francesca Bonello, Maria Teresa Petrucci, Anna Marina Liberati, Concetta Conticello, Stelvio Ballanti, Pellegrino Musto, Attilio Olivieri, Giulia Benevolo, Andrea Capra, Milena Gilestro, Piero Galieni, Michele Cavo, Agostina Siniscalchi, Antonio Palumbo, Vittorio Montefusco, Gianluca Gaidano, Paola Omedé, Mario Boccadoro, and Sara Bringhen

Disclosures: RM has received honoraria from Amgen, Celgene, Takeda and Janssen and served on the advisory boards for Janssen. MTP has received honoraria from Celgene, Janssen-Cilag, BMS, Takeda, and Amgen; has served on the advisory boards for Celgene, Janssen-Cilag, BMS, Takeda, and Amgen. AML has received honoraria from Janssen, Celgene, Bristol-Myers Squibb, Servier; has received clinical trial support from Novartis, AbbVie, Roche, Amgen, Celgene; has served on the advisory boards of AbbVie, Amgen, Takeda, Servier; and has undertaken consultancy for Incyte. StB has received honoraria for attending meetings from Janssen and Celgene. PM has received personal fees from Amgen, Novartis, BMS, Celgene, Janssen and Takeda. GB has served on the advisory boards for Novartis, Celgene, and Amgen. MC has received grants from Janssen and Celgene; has received personal fees from Janssen, Celgene, Amgen, BMS and Takeda. AP is currently a GlaxoSmithKline AG employee. VM has received speaking fees from and served on the advisory boards for Amgen, Celgene, Janssen, and Takeda. GG has served on the advisory boards for Janssen, AbbVie, Astra-Zeneca and Sunesys; has served on the speakers' bureaus for Janssen, Gilead and AbbVie. PO has served on the advisory board for Janssen. MB has received honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and AbbVie; has received research funding from Sanofi, Celgene, Amgen, Janssen, Novartis, Bristol-Myers Squibb, and Mundipharma. SB has received honoraria from Bristol-Myers Squibb, Celgene, Amgen and Janssen; has served on the advisory boards for Amgen, Karyopharm, Janssen and Celgene; and has received consultancy fees from Takeda and Janssen. The remaining authors declare no competing financial interests.

Contributions: Substantial contributions to the conception or design: RM, FB, PO, MB, and SB. Acquisition, analysis, or interpretation of data: all authors. First draft: RM, FB, AC, MG, PO, and SB. Statistical analysis: AC. Supervision: MB and SB. Critical revision for important intellectual content: all authors. Final approval of the version to be published: all authors. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: all authors.